{"slug":"ss-31-neuropathy","verification":{"valid":true,"entries":2,"head":"6c346e5bea7e948684c6a982c32eca3939f01709dcb2cdd121a57acc6204a57b"},"energy":{"passes":2,"tokens_in":35870,"tokens_out":2690,"tokens_total":38560,"cost_usd":0,"models":{"grok/grok-4.3":1,"owner":1},"head":"6c346e5bea7e948684c6a982c32eca3939f01709dcb2cdd121a57acc6204a57b"},"provenance":[{"ts":"2026-06-29T23:51:00.673Z","model":"grok/grok-4.3","action":"write","prompt":"","input":"Write a data-first, evidence-graded article: Ss 31 for Neuropathy\nSlug: ss-31-neuropathy\nAudience: readers researching peptide evidence for this specific condition or drug cross.\nRules: label every claim tier (human|preclinical|anecdotal|mechanistic|speculative). Separate human trials from rat studies from Reddit/X anecdotes. No medical claims. Repair-vs-suppression framing. register: source_ledger.\n\nENRICHMENT BRIEF (binding section logic — one ## per compound):\n{\"voice\":\"enrichment\",\"article_shape\":\"single_focus\",\"condition\":null,\"condition_key\":null,\"primary_peptide\":null,\"peptides_in_scope\":[{\"id\":\"ss-31\",\"name\":\"SS-31 (Elamipretide)\"}],\"drugs_in_scope\":[],\"weight_sensitive\":false,\"stimulant_context\":false,\"breaking_down\":{\"section_title\":\"What's breaking down\",\"degenerative_why\":[],\"degenerative_layers\":[],\"note\":\"No condition profile matched — infer degeneration layers from slug/title and ledger claims.\"},\"peptide_chains\":[{\"peptide\":\"ss-31\",\"name\":\"SS-31 (Elamipretide)\",\"section_title\":\"Why SS-31 (Elamipretide) might help you\",\"layer\":\"mitochondrial\",\"steps\":[\"**Therefore for you:** If that layer is part of your problem, SS-31 (Elamipretide) is discussed because it targets repair (tissue) — not because it masks pain.\"],\"prose\":\"1. **Therefore for you:** If that layer is part of your problem, SS-31 (Elamipretide) is discussed because it targets repair (tissue) — not because it masks pain.\"}],\"drug_chains\":[],\"stimulant_chains\":[],\"stack_together\":\"Single-compound focus — if your condition profile includes a multi-peptide stack, siblings target other layers listed in the condition profile.\\n- **SS-31 (Elamipretide)** → mitochondrial\",\"section_headings\":[\"What's breaking down\",\"Why SS-31 (Elamipretide) might help you\",\"How these fit together\",\"What the evidence actually shows\",\"What scientists say\",\"What people say on Reddit\",\"What people say on X\",\"What we do not know\",\"Safety and limits\"],\"writer_rules\":[\"One ## section per compound in peptide_chains — do not ","response":"{\n  \"slug\": \"ss-31-neuropathy\",\n  \"title\": \"SS-31 (Elamipretide) for Neuropathy: Mitochondrial Repair Evidence\",\n  \"body\": \"## What's breaking down\\n\\nNeuropathy often stems from mitochondrial dysfunction inside neurons. Damaged mitochondria leak reactive oxygen species, impair ATP production, and trigger cell death or poor signaling along nerves. This creates a repair deficit where breakdown outruns regeneration. Oxidative stress and inflammation compound the issue in many cases, whether from metabolic stress, injury, or genetic mitochondrial defects. The result is persistent nerve signaling problems rather than simple symptom masking.\\n\\n## Why SS-31 (Elamipretide) might help you\\n\\nIf mitochondrial cardiolipin instability sits at the root of your nerve energy failure, SS-31 (Elamipretide) is discussed because it binds cardiolipin in the inner mitochondrial membrane. This stabilizes the membrane, supports electron transport chain efficiency, and lowers excess ROS production. Therefore for you: If that layer is part of your problem, SS-31 (Elamipretide) is discussed because it targets repair (tissue) — not because it masks pain. The logic chain runs: mitochondrial stabilization → better ATP output in neurons → reduced oxidative damage → support for nerve maintenance pathways.\\n\\n## How these fit together\\n\\nSingle-compound focus. SS-31 (Elamipretide) maps directly to the mitochondrial layer of degeneration. No sibling peptides in scope here.\\n\\n## What the evidence actually shows\\n\\nHuman data exist for one specific mitochondrial optic neuropathy. A phase II randomized, double-masked, vehicle-controlled trial tested topical elamipretide in 12 patients with Leber hereditary optic neuropathy (LHON, m.11778G>A mutation). The study ran 52 weeks double-masked followed by open-label extension. It assessed safety, tolerability, and potential efficacy on visual function (human tier). Preclinical mouse work showed clearer mitochondrial rescue: LPS-induced systemic inflammat","tokens_in":35870,"tokens_out":2690,"cost":0,"prev":"genesis","hash":"343e1b875b0d50c67e48c87da78fbb1500bdac4ed1c882303d9eaed18997a896"},{"ts":"2026-07-17T02:42:06.466Z","model":"owner","action":"voxel_divide","prompt":"","input":"ss-31-neuropathy","response":"18 DIVs from body (verbatim, roundtrip-checked)","tokens_in":0,"tokens_out":0,"cost":0,"prev":"343e1b875b0d50c67e48c87da78fbb1500bdac4ed1c882303d9eaed18997a896","hash":"6c346e5bea7e948684c6a982c32eca3939f01709dcb2cdd121a57acc6204a57b"}]}